Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age.

Sharon Hui Xuan TanAlex R CookDerrick HengBenjamin OngDavid C LyeKelvin B Tan

Published in: The New England journal of medicine (2022)

During a period when the omicron variant was predominant, BNT162b2 vaccination reduced the risks of SARS-CoV-2 infection and Covid-19-related hospitalization among children 5 to 11 years of age.

Keyphrases

young adults
coronavirus disease
sars cov
randomized controlled trial
systematic review
respiratory syndrome coronavirus
risk assessment